Real‐world efficacy of single‐agent belantamab mafodotin in relapsed systemic <scp>AL</scp> amyloidosis
Jahanzaib Khwaja, Joshua Bomsztyk, Maria Atta, Ceri Bygrave, Adam Forbes, Senthil Durairaj, Savio Fernandes, James G. Taylor, Pamela Paterson, Gillian Brearton, Charles Crawley, Oonagh Sheehy, Rachel M. Brown, Richard Soutar, Mamta Garg, Andrzej Rydzewski, Krzysztof Jamroziak, Shameem Mahmood, Ashutosh Wechalekar
Abstract
Systemic light chain (AL) amyloidosis is a relapsing plasma cell disorder. Therapy is limited, particularly for triple-class refractory disease. We report the use of belantamab mafodotin, a BCMA-directed drug-antibody conjugate, for relapsed AL amyloidosis, including patients traditionally excluded from clinical trials. Thirty-one patients were reviewed, with a median of three prior lines of therapy. The median follow-up was 12 months (95% CI 4-19), and a median of five doses were delivered. The best haematological overall response rate was 71%, and the complete/very good partial response was 58%. Sixty-eight percent had keratopathy and improved in all. Belantamab mafodotin has high efficacy and good tolerability in patients with relapsed AL amyloidosis.